Semax

Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-7), incorporating the core ACTH 4-7 pharmacophore sequence (Met-Glu-His-Phe) extended with a C-terminal Pro-Gly-Pro sequence to alter in vitro stability characteristics relative to the native ACTH fragment. The Pro-Gly-Pro extension employs the same C-terminal stabilization strategy observed in related neuropeptide research analogues and has been characterized in published preclinical studies. Investigated in preclinical and in vitro laboratory models examining neurotrophic factor pathway activity, BDNF signaling pathway modulation, central nervous system receptor signaling, ischemic signaling pathway models, dopaminergic pathway activity, and hypothalamic-pituitary axis signaling research. Frequently referenced in published preclinical literature — including Russian Academy of Sciences research — examining neuropeptide receptor interactions and CNS pathway modulation. For Research Use Only — Not for Human or Veterinary Use.